Jubilant Pharmova Reports Strong FY2026 Revenue Growth and Debt Reduction Plan

Jubilant Pharmova Limited announced its fiscal year 2026 financial results, revealing a 14% year-over-year revenue increase to ₹8,280 crore. The fourth quarter of FY2026 saw revenue climb 19% to ₹2,290 crore.

Financial Highlights

For the full fiscal year 2026, the company posted revenue of ₹8,280 crore. EBITDA for the year was ₹1,326 crore, with a margin of 15.9%. Normalized Profit After Tax (PAT) for FY2026 was ₹442 crore.

Strategic Focus and Challenges

The company is expanding its CDMO sterile injectables capacity, with new lines at its Spokane facility expected to drive growth. However, Jubilant Pharmova is also addressing challenges such as supply shortages in its Radiopharma business and ongoing losses at its Montreal CMO facility. These factors are creating near-term margin pressure.

Path to Zero Net Debt

Jubilant Pharmova has laid out a clear strategy to eliminate its net debt by fiscal year 2030. The company's net debt stood at ₹1,952 crore at the end of FY2026, with capital expenditure for the year reaching ₹1,668 crore.

Future Growth Drivers and Turnaround

New CDMO sterile injectables lines are being prioritized for tech transfer and commercialization, targeting significant revenue contributions. While the Radiopharma segment faces temporary margin pressure in the first half of FY2027 due to supply issues, the Ruby-Fill franchise shows robust growth. The company anticipates a substantial reduction in losses from the Montreal plant starting in FY2028, with new capacity contributions expected by FY2029.

Key Risks

Investors should watch for continued margin pressure in early FY2027 linked to Radiopharma supply. The turnaround of the loss-making Montreal CMO facility, which incurred approximately ₹200 crore in losses in FY2026, is a critical factor, with improvements projected from FY2028. The company's effective tax rate remains elevated at around 33%.

Peer Context

Jubilant Pharmova competes in the CDMO market with companies like Syngene International and Laurus Labs. Its focus on sterile injectables and radiopharmaceuticals provides a distinct market position. The company's integrated approach and growth in specific franchises like Ruby-Fill are key differentiators in the competitive landscape.

Key Metrics to Track

Investors will monitor the progress of CDMO Line 3 commercialization, expected in late FY2027. Performance in the first half of FY2027 against margin recovery targets for the second half will be important. Deleveraging progress and a reduction in losses at the Montreal facility remain key metrics to watch.